Mr. Shuber is an accomplished senior executive with 20+ years of experience in the development of molecular diagnostic assays within the clinical laboratory and biotech industry. He has a demonstrated track record of developing, validating, and transferring assays from inception to commercialization within the prenatal and oncology space. Mr. Shuber previously co-founded Exact Sciences and developed the first non-invasive diagnostic test for colorectal cancer screening. Later Mr. Shuber co-founded Predictive Biosciences and developed the first diagnostic combining protein and DNA. He has over 100 issued and pending patent applications.
David Zuzga, Ph.D. - Founder/CEO
Dr. Zuzga is an entrepreneur and research scientist. He is an Assistant Professor at La Salle University and a senior consultant with Envisage, an Ethos LifeScience Advisors Company. He received his bachelor’s degree in Biopsychology from Vassar College and his Ph.D. from the Kimmel Cancer Center at Thomas Jefferson University. Dr. Zuzga has worked at the Harvard Medical School and at the CNS Gene Therapy Center at Thomas Jefferson where he co-developed a Parkinson Disease therapy and a nootropic drug, both of which were licensed for development. Working with Dr. Pitari, Dr. Zuzga’s research characterized changes to the VASP protein in colorectal cancer that are highly associated with disease progression and this work serves as the foundation of BioDetego’s VASPfore technology.
GianMario Pitari, M.D., Ph.D. - Founder/CSO
Dr. Pitari is an entrepreneur, physician and research scientist with expertise in Translational Oncology. Dr. Pitari received his M.D. and Ph.D. from the University of Catania Medical School (Italy). He is a former Associate Professor at Thomas Jefferson University where his laboratory discovered the role of VASP in cancer progression and its clinical utility as a biomarker. At Jefferson Dr. Pitari was the Director of the Laboratory of Investigative Medicine, which performs studies to support the development of drugs in early phase clinical trials. He also co-founded and serves as the Director of R&D of Vera Salus Ricerca, S.R.L. an Italian-based contract research organization. Dr. Pitari has been the recipient of many prestigious research awards from public and private organizations, including the National Institute of Health (NIH), the American Institute for Cancer Research (AICR), the Pennsylvania Dept. Health, and the Prevent Cancer Foundation
Robert Hrubiec, J.D., Ph.D. - Intellectual Property
Dr. Hubriec is a Business Advisory Board member and provides IP and general legal counsel. He is a seasoned intellectual property attorney and business executive with over 25 years in-house experience in both large and small pharmaceutical and biotechnology companies. Previously, Dr. Hrubiec served as a Vice President and Chief IP Counsel of Cephalon, Inc., a mid-sized biopharmaceutical company and as an Intellectual Property Attorney for GlaxoSmithKline, a multi-billion-dollar pharmaceutical company. Mr. Hrubiec earned his doctoral degree in Synthetic Organic Chemistry from the University of Connecticut. He also served a post-doctoral fellowship (Pharmacology/Biochemistry) at Yale University School of Medicine and earned his law degree from North Carolina Central University School of Law. He is currently President of InnoventivIP, an intellectual property consulting firm.
Mark Myslinski - Commercialization
Mr. Myslinski is a Business Advisory Board member and brings cancer diagnostic development and commercialization expertise to BioDetego. He is currently the Chief Commercialization Officer at the KEW Group, a NGS precision medicine company with a focus on oncology. Previously Mr. Myslinski sat on the Board of Directors of Mdx Health, a Belgium-based, publicly listed cancer diagnostics company and was a SVP and the Chief Commercial Officer for Saladax BioMedical, Inc., the President and CEO of RedPath Integrated Pathology, Inc., and before that he was a Johnson & Johnson executive where his responsibilities included building a new, worldwide Evidence-Based Medicine function for the Ortho-Clinical Diagnostics unit and as General Manager of Johnson & Johnson's Veridex, LLC, a division focused on cancer diagnostics. Mr. Myslinski also held executive roles in the venture-backed start-ups Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on oncology.
Massimo Cristofanilli, M.D. - Clinical Advisor
Dr. Cristofanilli is a medical oncologist and a member of BioDetego’s Clinical Advisory Board. He is an internationally renowned expert in translational research and cancer biomarker development. He is the Associate Director of Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Significantly, Dr. Cristofanilli was a key collaborator in the development of the Veridex/Johnson&Johnson CELLSEARCH® CTC cancer diagnostic test. Dr. Cristofanilli provides expert guidance on clinical trials design and execution.
Juan Palazzo, M.D. - Clinical Advisor
Dr. Palazzo is a Professor of Pathology at Thomas Jefferson University and a member of BioDetego’s Clinical Advisory Board. Dr. Palazzo is a renowned pathologist with extensive clinical and research experience in breast and colon cancer. His current research program is focused on elucidating biomarkers to predict tumor progression and therapeutic resistance. His clinical and research expertise is directly translatable to research & development activities required to commercialize VASPfre-CRC.